Trial Profile
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2017
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
- Sponsors Shenzhen Innovation Immunotechnology
- 08 Dec 2017 New trial record